Advertisement

TheBodyPRO.com Covers CROI 2017

News

HIV Researchers Reassert Treatment Is Prevention

March 8, 2017

We need to meet people where they are at. If you do not want to have a medical provider, but you are interested in being on [pre-exposure prophylaxis], then we should create an environment where it is possible for you to get that.

-- Matthew Golden, M.D.

In an interview on behalf of IFARA at CROI 2017, Fred Schaich spoke with Deborah Donnell and Matthew Golden about how getting people onto HIV treatment also prevents the spread of the virus. One of the first urban areas in the U.S. to achieve the World Health Organization's 90-90-90 goals was King County, Washington, which includes Seattle. 90-90-90 refers to 90% of those living with HIV being diagnosed, 90% of those diagnosed being on antitretroviral treatment and 90% of those on treatment having undetectable viral loads. Studies have shown that people who are virally suppressed do not pass HIV on to their sex partners.

Meanwhile, the first "90 goal" is within reach in some South African communities where door-to-door visits from health workers have tested almost 85% of the population. Sub-Saharan Africa is seeing an unprecedented number of young people infected. To reach this population, clinic spaces and prevention messages must be made youth-friendly. In general, the delivery of medical care must be structured to accommodate the people for whom it is intended.

Watch the video to learn more:



About the panelist:

  • Deborah Donnell, Ph.D., Global Health, University of Washington, Seattle, and Fred Hutchinson Cancer Research Center.
  • Matthew Golden, M.D., Division of Allergy and Infectious Diseases, University of Washington, Seattle, and Public Health -- Seattle & King County.

The video above has been posted on TheBodyPRO.com with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.

Barbara Jungwirth is a freelance writer and translator based in New York.

Follow Barbara on Twitter: @reliabletran.


Related Stories

Safety Important in Pre-Exposure Prophylaxis Trials
The Need to Advocate for Fair HIV Drug Prices



This article was provided by TheBodyPRO.com. It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.